Phoenix Rising tells QMUL: release the PACE trial data
Mark Berry, Acting CEO of Phoenix Rising, presents the Board of Directors’ open letter to Queen Mary University of London (QMUL) urging them to release the PACE trial data, and hopes that other non-UK organisations will join British charities in the same request...
Discuss the article on the Forums.

Jason and Evans: To PEM or not to PEM? That is the question for case definition

Discussion in 'General ME/CFS News' started by Ember, Apr 27, 2012.

  1. justy

    justy Senior Member

    Messages:
    4,274
    Likes:
    7,495
    U.K
    Hi Ember - i dont know if we are talking at cross purposes - but im getting muddled as to what we are discussing. I dont think we are really disagreeing. Sorry - finding it hard to keep up today (re your other thread too)

    Dai - i agree that using more severely ill patients in trials is a good idea - especially when the very severe are so often left out of all trials - onviously there are issues with this - travel energy expended to take part etc, which is why tirals may end up with less severe or milder patients.

    All the best, Justy.
     

See more popular forum discussions.

Share This Page